Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 28 AUGUST 2026

The Board announces that the first resolution as set out in the EGM Notice was duly passed by the Shareholders by way of poll at the EGM held on 28 August 2026. The second resolution as set out in the EGM Notice was not passed by the Shareholders by way of poll at the EGM held on 28 August 2026.

References are made to the circular (the "**Circular**") and notice of extraordinary general meeting (the "**EGM Notice**") issued by China NT Pharma Group Company Limited (the "**Company**") dated 10 August 2026 in connection with the extraordinary general meeting (the "**EGM**"). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EGM

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce the poll results of the EGM held at Unit 2102, 21/F, Shun Tak Centre – West Tower, 168–200 Connaught Road Central, Hong Kong on 28 August 2026 at 11:00 a.m.

All of the Directors attended the EGM in person or by electronic means.

As at the date of the EGM, there are a total of 948,997,694 Shares in issue. Pursuant to Rule 13.40 of the Listing Rules, the Subscribers, their respective associates, any parties acting in concert with each of them and the Shareholders who are involved in or interested in the Subscription Agreements and the transactions contemplated thereunder (i.e. the Subscriptions, the Loan Capitalisation and the Specific Mandate), which hold 505,651,342 Shares, were required to abstain from voting in respect of the resolution(s) to approve the Subscription Agreements and the transactions contemplated thereunder (i.e. the Subscriptions, the Loan Capitalisation and the Specific Mandate) at the EGM. Accordingly, in respect of the first resolution at the EGM, the total number of shares entitled to vote is 443,346,352. In respect of the second resolution at the EGM, the total number of shares entitled to vote is 948,997,694.

The Hong Kong branch share registrar and transfer office of the Company, Tricor Investor Services Limited, was appointed as the scrutineer for vote taking at the EGM.

The Board is pleased to announce that the first resolution as set out in the EGM Notice has been duly passed by the Shareholders by way of poll at the EGM. The second resolution was not passed by the Shareholders by way of poll at the EGM. The details of poll results are as follows:

Ordinary Resolutions [(1)(2)]		**No. of Votes (%)**	
		For	**Against**
1.	To confirm, approve and ratify the Subscription Agreements and the matters contemplated thereunder, including but not limited to the specific mandate to allot and issue the Subscription Shares by the Company to the Subscribers pursuant to the Subscription Agreements, and to authorise any one or more of the Directors to do all such acts and things and execute all such documents which he/she/they consider necessary, desirable or expedient for the purpose of, or in connection with the implementation of and giving effect to the Subscription Agreements and the transactions contemplated thereunder.	268,137,216 (100.00%)	0 (0.00%)
2.	To approve the appointment of CCTH CPA Limited as the auditor of the Company and to authorise the board of directors of the Company to fix their remuneration.	9,350 (0.01%)	584,572,725 (99.99%)

Note:

(1) The full text of the Resolutions is set out in EGM Notice.

(2) As disclosed in the circular dated 10 August 2026, the Subscribers, their respective associates, any parties acting in concert with each of them and the Shareholders who are involved in or interested in the Subscription Agreements and the transactions contemplated thereunder (i.e. the Subscriptions, the Loan Capitalisation and the Specific Mandate), will be required to abstain from voting in respect of the resolution(s) to approve the Subscription Agreements and the transactions contemplated thereunder (i.e. the Subscriptions, the Loan Capitalisation and the Specific Mandate) at the Meeting. Accordingly, in respect of the first resolution at the EGM, the total number of shares entitled to vote is 443,346,352. According to the scrutineers' certificate from Tricor Investor Services Limited, in respect of the first resolution, 414,657,362 shares voted in favour, with none against. However, 146,520,146 shares held by Mr. Ieong Iat through the Central Clearing and Settlement System were invalidly cast on the first resolution. Had his vote been disregarded, the votes in favour would have totalled 268,137,216, with none against.

As more than 50% of the valid votes were cast in favour of the first resolution, the resolution was duly passed as an ordinary resolution of the Company.

As less than 50% of the valid votes were cast in favour of the second resolution, the second resolution was not passed as an ordinary resolution of the Company. Accordingly, CCTH CPA Limited will not be appointed as the auditor of the Company. The Board will continue its efforts to identify a suitable auditor to fill the casual vacancy and a further extraordinary general meeting will be convened to consider the appointment of a new auditor. Further announcement(s) will be made by the Company as and when appropriate in accordance with the Listing Rules.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 28 August 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.